http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102240928-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d97e77bf0e22ff5c33c98af9a77ebd43 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357 |
| filingDate | 2019-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c391a7600d91f5027d9714c6613b31f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a21544039b00cb935f8adb86f38b8b4 |
| publicationDate | 2021-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102240928-B1 |
| titleOfInvention | Pharmaceutical composition for prevention or treatment of central nervous system diseases by TDP-43 mediated stress granule aggregation in cells via inhibiting ATXN2 |
| abstract | The present invention relates to a pharmaceutical composition for the prevention and treatment of central nervous system diseases caused by the generation of stress granules of cells, and in detail, in the group consisting of Epiandrosterone, Topiramate, and pharmaceutically acceptable salts thereof By inhibiting ATXN2 containing any one selected as an active ingredient, the abnormal aggregation of TDP-43 protein is inhibited, thereby significantly reducing the production of stress granules in central nervous system diseases such as amyotrophic lateral sclerosis and frontal dementia cells. Atrophic lateral sclerosis or frontal dementia can be usefully used in the prevention and development of therapeutic agents. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022203097-A1 |
| priorityDate | 2019-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.